Pfizer (PFE), BioNTech SE (BNTX) Say Three Vaccine Doses Neutralize Omicron Variant - DJ
Tweet
Share
E-mail
Get Alerts PFE Hot Sheet
Price: $27.74 +0.29%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 6.9%
EPS Growth %: -12.6%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 6.9%
EPS Growth %: -12.6%
Join SI Premium – FREE
(Updated - December 8, 2021 6:53 AM EST)
Pfizer (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) said a third dose of their vaccine neutralized Omicron in lab tests, according to Dow Jones.
The two-dose regimen was significantly less effective.
A third dose increased antibodies 25-fold compared to two doses in the variant. Two doses may prove effective in preventing severe illness.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- EMA panel backs Novo Nordisk's Sogroya for children's growth disorder
- GameStop CEO Cohen buys 1.15M shares
- OS Therapies gets MHRA lead role in global OST-HER2 review
Create E-mail Alert Related Categories
FDA, Hot FDA News, Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
